International Journal of Pharmaceutical and Phytopharmacological Research
ISSN (Print): 2250-1029
ISSN (Online): 2249-6084
Publish with eIJPPR Submission
2026   Volume 16   Issue 2

Digital Twins of Natural Product Pharmacology: Modeling Compound Exposure, Target Engagement, Pathway Response, Safety Risk, and Therapeutic Outcomes
Download PDF


, ,
  1. Department of AI for Bulgarian Rose and Propolis Bioactives, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
  2. Department of Computational Pharmacology for Antioxidant Assays, Faculty of Pharmacy, University of Plovdiv, Plovdiv, Bulgaria.
Citation
Vancouver
Petrova E, Georgiev I, Stoyanov N. Digital Twins of Natural Product Pharmacology: Modeling Compound Exposure, Target Engagement, Pathway Response, Safety Risk, and Therapeutic Outcomes. Int J Pharm Phytopharmacol Res. 2026;16(2):36-52. https://doi.org/10.51847/wOT5wAD4Me
APA
Petrova, E., Georgiev, I., & Stoyanov, N. (2026). Digital Twins of Natural Product Pharmacology: Modeling Compound Exposure, Target Engagement, Pathway Response, Safety Risk, and Therapeutic Outcomes. International Journal of Pharmaceutical And Phytopharmacological Research, 16(2), 36-52. https://doi.org/10.51847/wOT5wAD4Me
Download citation:   EndNote   RIS
Article Link:
Downloads: 21
Views: 91
Abstract

Natural product pharmacology presents a distinctive modeling challenge because botanical materials and derived preparations may contain multiple constituents with variable composition, uncertain bioavailability, overlapping targets, pathway-level effects, and context-dependent safety liabilities. This article proposes a conceptual digital twin framework that connects authenticated natural product identity with compound exposure, target engagement, pathway response, safety-risk interpretation, and bounded therapeutic outcome simulation. The framework begins with botanical provenance, phytochemical composition, chemical identity, and evidence quality before incorporating absorption, distribution, metabolism, excretion, physiologically based pharmacokinetic logic where supported, population variability, and pharmacokinetic–pharmacodynamic relationships. Target engagement is represented through graded confidence derived from binding, interaction, proteomic, functional, and attainable-exposure evidence rather than computational prediction alone. Pathway-response modeling integrates network and systems pharmacology with disease or phenotype context, while safety assessment incorporates ADMET evidence, toxicity findings, herb–drug interaction mechanisms, and pharmacovigilance signals. Virtual patient and virtual population logic may support scenario analysis and research prioritization, but simulated therapeutic outcomes remain hypotheses rather than demonstrations of efficacy, safety, clinical utility, or treatment benefit. Uncertainty quantification, expert review, internal and external validation planning, experimental confirmation, feedback updating, and a no-clinical-claim boundary are therefore treated as integral architectural components. The principal contribution is a staged and evidence-bounded digital twin architecture designed to strengthen mechanistic hypothesis generation and translational planning in natural product research without replacing experimental pharmacology, toxicology, clinical investigation, or accountable professional judgment.

Related articles:
Most viewed articles:
Naproxen in Pain and Inflammation – A Review
Vol 11 Issue 1, 2021 | Svetoslav Nikolaev Stoev
An Overview on Emulgel
Vol 9 Issue 1, 2019 | Sreevidya V.S
Volume 16
Issue 4
2026

Call for Papers
[email protected]
Issues
Associations
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2026 International Journal of Pharmaceutical and Phytopharmacological Research
Authors retain copyright of their article if they are accepted for publication.